Enliven Therapeutics's market cap is currently ―. The company's EPS TTM is $-2.18; its P/E ratio is -7.88; Enliven Therapeutics is scheduled to report earnings on May 9, 2024, and the estimated EPS forecast is $-0.54. See an overview of income statement, balance sheet, and cash flow financials.

	Sep 23	Jun 23	Apr 23	Jan 23	Dec 22
Income Statement	-
Total Revenue	-	-	-	-	-
Gross Profit	-	-	-	-	-
EBIT	$ -20.77M	$ -16.72M	$ -116.23K	$ -58.88K	$ 32.27M
EBITDA	$ -20.77M	$ -17.48M	-	-	$ 32.26M
Net Income Common Stockholders	$ -20.77M	$ -16.72M	$ -116.23K	$ -58.88K	$ 32.19M
Balance Sheet	-
Cash, Cash Equivalents and Short-Term Investments	$ 263.48M	$ 277.87M	$ 338.86K	$ 323.89K	$ 88.20M
Total Assets	$ 274.04M	$ 288.50M	$ 1.79M	$ 797.20K	$ 91.96M
Total Debt	$ 0.00	$ 0.00	$ 0.00	$ 0.00	$ 0.00
Net Debt	$ -263.48M	$ -277.87M	$ -338.86K	$ -323.89K	$ -88.20M
Total Liabilities	$ 12.29M	$ 9.51M	$ 233.55K	$ 157.81K	$ 1.83M
Stockholders Equity	$ 261.75M	$ 278.99M	$ 1.56M	$ 639.39K	$ 90.13M
Cash Flow	-
Free Cash Flow	$ -15.91M	$ -12.14M	$ -99.53K	-	$ 33.12M
Operating Cash Flow	$ -15.89M	$ -12.05M	$ -74.29K	-	$ -1.88M
Investing Cash Flow	$ -35.55M	$ -151.52M	$ -25.23K	-	$ 41.82M
Financing Cash Flow	$ -425.00K	$ -2.82M	$ 114.50K	-	$ -1.23M

Currency in USD

Enliven Therapeutics Earnings and Revenue History

Income Statement >

Enliven Therapeutics Debt to Assets

Balance Sheet >

Enliven Therapeutics Cash Flow

Cash Flow >

Enliven Therapeutics Forecast EPS vs Actual EPS

Earnings >

Get More with TipRanks Premium

What's Included in PREMIUM?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing